Needham & Company LLC Reaffirms “Buy” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Needham & Company LLC reiterated their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $23.00 price target on the stock.

A number of other research firms have also recently issued reports on ARTV. TD Cowen started coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Jefferies Financial Group started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating and a $21.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $10.06 on Wednesday. The company’s 50-day simple moving average is $12.57. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, analysts forecast that Artiva Biotherapeutics will post -4.6 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently made changes to their positions in the stock. Barclays PLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $304,000. Wellington Management Group LLP acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $2,912,000. State Street Corp acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $1,337,000. Samsara BioCapital LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $4,506,000. Finally, RA Capital Management L.P. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $152,234,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.